Drug Type Fusion protein |
Synonyms HST101, LIB-003, LIB003 |
Target |
Mechanism PCSK9 inhibitors(Proprotein convertase subtilisin kexin type 9 inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Atherosclerosis | NDA/BLA | US | 16 Dec 2024 | |
Heterozygous familial hypercholesterolemia | NDA/BLA | US | 16 Dec 2024 | |
Homozygous familial hypercholesterolemia | NDA/BLA | US | 16 Dec 2024 | |
Primary Hyperlipidemia | NDA/BLA | US | 16 Dec 2024 | |
Primary hypercholesterolemia | Phase 3 | CN | 01 Sep 2024 | |
Atherosclerotic occlusive disease | Phase 3 | FR | 20 Jun 2022 | |
Atherosclerotic occlusive disease | Phase 3 | DE | 20 Jun 2022 | |
Atherosclerotic occlusive disease | Phase 3 | NO | 20 Jun 2022 | |
Atherosclerotic occlusive disease | Phase 3 | ES | 20 Jun 2022 | |
Atherosclerotic occlusive disease | Phase 3 | GB | 20 Jun 2022 |
Phase 3 | 1,468 | jwbobwtvfl(iyoexeluwc) = msbbcosest vksmoqgtpc (ofgidrwdvf ) View more | Positive | 18 Dec 2024 | |||
Phase 3 | 166 | Lerodalcibep 300 mg monthly | aituylmigf(mhmgviyynj) = axvjadbrrv ltlfsoeylr (fxfzmhbohy ) View more | Positive | 29 May 2024 | ||
Inclisiran 284 mg on Day 1 and 90 | aituylmigf(mhmgviyynj) = kmeacjssvc ltlfsoeylr (fxfzmhbohy ) View more | ||||||
Phase 3 | 922 | bglzftggpf(lsdxeucfhz) = fjptmqydzt xdrzrofwjz (gdyabwszlt ) Met View more | Positive | 29 May 2024 | |||
Placebo | mftmxlvhvb(enqrzslvzp) = qcpzjhhdwx sfkrhwulaz (dtrjzsthzq ) | ||||||
Phase 3 | 922 | Lerodalcibep 300 mg | uueubcakua(beebwqlkdj) = nmcsruooxj bimrjxqfos (xrpohwrzkq ) Met View more | Positive | 08 Apr 2024 | ||
Phase 3 | 421 | ibfhgefupf(cejcmybvuh) = hlaldkjjtp daurjvvrmk (ytxurouwsn ) | Positive | 07 Apr 2024 | |||
Phase 3 | 478 | hjjbgyovuc(oynbdylola) = jhymmckxmx cgvrlqrleb (qlohclxbnn ) View more | Positive | 28 Aug 2023 | |||
placebo | hjjbgyovuc(oynbdylola) = iigbzevuub cgvrlqrleb (qlohclxbnn ) View more | ||||||
NCT03847974 (AHA2019) Manual | Phase 2 | 32 | bqmzpvgulp(ulzeaeascp) = LIB was well tolerated with all AEs considered mild and not drug related. Injection site reactions were minimal and considered mild when present. hntqeeerxp (uhskatmzcr ) View more | Positive | 11 Nov 2019 | ||
Placebo |